Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking  these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association. This research was presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans on Saturday, June 6 at 12:30 p.m. CT/1:30 p.m. CT, abstract number 2199-P.

The American Heart Association launches stroke coordinator certification to elevate quality of stroke care

League-wide group of NWSL players join Savy King and the American Heart Association to champion CPR and AED education during National CPR and AED Awareness Week

Eight companies named to the American Heart Association Heart and Brain Health Accelerator within the 2026 MedTech Innovator cohort

The American Heart Association is providing $4.5 million in funding to establish a new research network as the first part of a multi-phase initiative aimed at improving heart transplant outcomes